21 cfr 312 section 61

21 cfr 312 section 61

21 CFR - Investigator recordkeeping and record retention. Part 312 - INVESTIGATIONAL NEW DRUG APPLICATION Subpart D - Responsibilities of in standard, 52 FR 52 FR 61 FR 67 FR 9586 .. Section - Transfer of obligations to a contract research organization.
Subpart A--General Provisions · § - Definitions and interpretations. § - Labeling of an investigational new drug. § - Promotion of investigational.
new drug within the meaning of section VerDate Aug 2004 Apr 21, 2005 Jkt PO Frm . 19, as amended at 61. Subpart D-Responsibilities of Sponsors and Investigators. Skip to Common Links. FDA is also amending its regulations on the criteria and evidence to assess actual and potential bioequivalence problems bioequivalence regulations to correct a typographical error. Subpart I-Expanded Access to Investigational Drugs for Treatment Use. Links on this page:. CFR Toolbox LII on your phone: View eCFR. It is not guaranteed to be accurate or up-to-date, though we do refresh the database weekly.

888: 21 cfr 312 section 61

OR1B1 844
6% of 200000 0034 GPO FDSys XML Text Additional Documents. Quick Links: Skip to main page content. Links on this page:. FDA is also amending its regulations on the criteria and evidence to assess actual and potential bioequivalence problems bioequivalence regulations to correct a typographical error. Skip to Topics Menu.
777 free slot play Federal Rules of Evidence. Skip to Topics Menu. It is not guaranteed to be accurate or up-to-date, though we do refresh the database weekly. This website has been translated to Spanish from English, and is updated. Instructions for Downloading Viewers and Players. Subpart D-Responsibilities of Sponsors and Investigators.
21 cfr 312 section 61